Parainfluenza virus vaccine - Pharmacia

Drug Profile

Parainfluenza virus vaccine - Pharmacia

Latest Information Update: 02 Aug 2002

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Parainfluenza virus infections

Most Recent Events

  • 06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
  • 27 Jul 1999 New profile, split from generic Parainfluenza virus vaccine profile
  • 27 Jul 1999 Preclinical development for Parainfluenza virus infections in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top